



Supporting Information

Supplementary material

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Wesselingh R. Prevalence, pathogenesis and spectrum of neurological symptoms in COVID-19 and post-COVID-19 syndrome: a narrative review. *Med J Aust* 2023; doi: 10.5694/mja2.52063.

Summary of the prevalence of neurological complications of coronavirus disease 2019 (COVID-19) reported in registries

Authors (year)	Country or region	Patients	Setting	Patient type	Any Neurological symptoms					Impaired consciousness			Cerebrovascular disorder		Peripheral neuropathy	Cranial neuropathies	Seizures	Ataxia	Movement disorders	Visual abnormalities	Dysautonomia
					Headache	Myalgia	Anosmia	Ageusia	ness	Encephalopathy	disorder	Sleep disorders	ny	ies	Ataxia	disorders	ies	omia			
Mao et al (2020)	China (Wuhan)	214	Inpatient	All	36.40%	13.10%	-	5.10%	5.60%	7.50%	-	-	-	8.90%	-	0.50%	-	-	1.40%	-	
Moro et al ¹ (2020)	Europe	Not reported	Not reported	Unclear	~100%	61.90%	50.40%	49.20%	39.80%	29.30%	21%	21%	10.70%	8.50%	-	8.10%	7.40%	5.20%	5.10%		
Karadas et al ² (2020)	Italy	239	Inpatient	All	34.70%	26.70%	15.10%	7.50%	6.70%	9.60%	-	3.70%	12.60%	0.40%	7.80%	-	2.50%	-	3.30%		
Frontera et al ³ (2021)	New York City	4491	Inpatient	All	88%	-	-	-	-	-	6.80%	1.90%	-	0.90%	-	1.60%	-	0.90%	-		
Nersesjan et al ⁴ (2021)	Copenhagen	61	Inpatient	All	Not reported	16.40%	-	29.50%	29.50%	-	-	-	-	3.30%	-	4.90%	-	-	-		
Kacem et al ⁵ (2021)	Tunisia	646	Inpatient	All	72.10%	41.10%	37.30%	37.9%	36.80%	-	-	-	37.30%	-	-	-	-	-	-	7.40%	
Espiritu et al ⁶ (2021)	Phillipines	10 881	Inpatient	All	18.40%	5.58%	2.35%	5%	3.11%	-	1.31%	-	-	0.49%	0.54%	0.88%	0.04%	0.03%	0.06%		
Chou et al ⁷ (2021)	Global	3055	Inpatient	All	15.50%	38%	-	28%	28%	17%	50%	-	-	2%	-	1%	-	3%	-	1%	
Chou et al ⁷ (2021)	Europe	214	Inpatient	All	7%	27%	-	23%	23%	10%	24%	-	-	2%	-	8%	-	-	-	8%	
Oliveira et al ⁸ (2021)	Northern Portugal	1261	Inpatient	All	36.20%	13.40%	9%	4.10%	3.70%	9.70%	10.10%	1.80%	2.60%	0.90%	-	1.50%	-	-	-	-	
Meppiel et al ⁹ (2020)	France	222	Inpatient	NeuroCOVID	-	10.80%	-	3.20%	1.80%	-	30.10%	26%	-	6.80%	4.50%	9.50%	-	3.60%	-	-	
Rifino et al ¹⁰ (2020)	Italy (Bergamo)	137	Inpatient	NeuroCOVID	-	2.20%	-	-	-	35.80%	3.60%	38.70%	-	35%	-	7.30%	-	5%	-	-	
Flores-Silva et al ¹¹ (2021)	Mexico City	1072	Inpatient	All	15.20%	41.70%	38.50%	7%	8%	13.10%	0.20%	0.80%	-	-	-	0.80%	-	-	-	-	
Romero-Sanchez et al ¹² (2020)	Spain (Albacete)	841	Inpatient	All	57.40%	14.10%	17.20%	4.90%	6.20%	13.90%	0.10%	1.70%	13%	-	-	0.70%	-	0.70%	-	2.50%	
Ding et al ¹³ (2020)	Wuhan	153	Outpatient	All	77.80%	31.40%	-	18.30%	18.30%	-	-	-	-	69.30%	-	-	-	-	3.30%	-	
Varatharaj et al ¹⁴ (2020)	UK	153	Inpatient	NeuroCOVID	-	-	-	-	-	31%	10.50%	62%	-	5%	-	-	-	-	-	-	
Mekkawy et al ¹⁵ (2022)	Egypt	582	Inpatient	All	48.63%	28.69%	21.65%	25.43%	25.43%	1.88%	2.07%	1.84%	-	2.24%	-	-	-	-	-	-	

Travi et al ¹⁶ (2020)	Italy (Milan)	901	Inpatient	All	30.20%	4.30%	-	9.10%	9.10%	-	0.60%	5.90%	-	-	-	2.10%	-	-	-	-
Yuksel et al ¹⁷ (2021)	Turkey (Ankara)	204	Inpatient	NeuroCO VID	-	13.70%	-	-	-	65.30%	-	31.70%	-	-	-	13.20%	-	-	-	-
Garcia-Azorin et al ¹⁸ (2020)	Spain	223	Both	NeuroCO VID	-	17.40%	25%	19.50%	-	-	-	-	-	-	-	-	-	-	-	-
Garcia-Azorin et al ¹⁹ (2020)	Spain	576	Inpatient	All	55.60%	23.80%	24.1%%	25.30%	-	17%	-	-	-	-	-	0.50%	1%	-	-	-
Bhansali et al (2021) ²⁰	India (Kolkata)	228	Inpatient	NeuroCO VID	-	-	-	-	-	-	21%	27.20%	-	6.80%	-	-	-	-	-	-
Vengalil et al (2021) ²¹	India	100	Inpatient	NeuroCO VID	-	7%%	5%	14.30%	7.60%	47%	23%	43%	-	10%	2%	5%	-	-	-	-

References

- 1 Moro E, Priori A, Beghi E, et al. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. *Eur J Neurol* 2020; 27: 1727-1737.
- 2 Karadas O, Ozturk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. *Neurol Sci* 2020; 41: 1991-1995.
- 3 Frontera JA, Sabadia S, Lalchan R, et al. A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. *Neurology* 2021; 96: e575-e586.
- 4 Nersesjan V, Amiri M, Lebech AM, et al. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. *J Neurol* 2021; 268: 3086-3104.
- 5 Kacem I, Gharbi A, Harizi C, et al. Characteristics, onset, and evolution of neurological symptoms in patients with COVID-19. *Neurol Sci* 2021; 42: 39-46.
- 6 Espiritu AI, Sy MCC, Anlacan VMM, et al. COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study). *J Neural Transm (Vienna)* 2021; 128: 1687-1703.
- 7 Chou SH, Beghi E, Helbok R, et al. Global Incidence of neurological manifestations among patients hospitalized with COVID-19 — a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. *JAMA Netw Open* 2021; 4: e2112131.
- 8 Oliveira V, Seabra M, Rodrigues R, et al. Neuro-COVID frequency and short-term outcome in the Northern Portuguese population. *Eur J Neurol* 2021; 28: 3360-3368.
- 9 Meppiel E, Peiffer-Smadja N, Maury A, et al. Neurologic manifestations associated with COVID-19: a multicentre registry. *Clin Microbiol Infect* 2021; 27: 458-466.
- 10 Rifino N, Corsori B, Agazzi E, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. *J Neurol* 2021; 268: 2331-2338.
- 11 Flores-Silva FD, Garcia-Grimshaw M, Valdes-Ferrer SI, et al. Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City. *PLoS One* 2021; 16: e0247433.
- 12 Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. *Neurology* 2020; 95: e1060-e1070.
- 13 Ding H, Yin S, Cheng Y, et al. Neurologic manifestations of nonhospitalized patients with COVID-19 in Wuhan, China. *MedComm (2020)* 2020; 1:253-256.
- 14 Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry* 2020; 7: 875-882.
- 15 Mekkawy DA, Hamdy S, Abdel-Naseer M, et al. Neurological manifestations in a cohort of Egyptian patients with COVID-19: a prospective, multicenter, observational study. *Brain Sci* 2022; 12: 74.
- 16 Travi G, Rossotti R, Merli M, et al. Neurological manifestations in patients hospitalized with COVID-19: a retrospective analysis from a large cohort in Northern Italy. *Eur J Neurosci* 2021; 53: 2912-2922.
- 17 Yuksel H, Gursoy GT, Dirik EB, et al. Neurological manifestations of COVID-19 in confirmed and probable cases: a descriptive study from a large tertiary care center. *J Clin Neurosci* 2021; 86: 97-102.
- 18 Garcia-Azorin D, Abildua MJA, Aguirre MEE, et al. Neurological presentations of COVID-19: findings from the Spanish Society of Neurology neuroCOVID-19 registry. *J Neurol Sci* 2021; 423: 117283.
- 19 Garcia-Azorin D, Trigo J, Martinez-Pias E, et al. Neurological symptoms in Covid-19 patients in the emergency department. *Brain Behav* 2021; 11: e02058.
- 20 Bhansali S, Bagrodia V, Choudhury S, et al. Spectrum of hospitalized NeuroCOVID diagnoses from a tertiary care neurology centre in Eastern India. *J Clin Neurosci* 2021; 93: 96-102.
- 21 Vengalil S, Mahale R, Chakradhar N, et al. The spectrum of Neuro-COVID: a study of a comprehensively investigated large cohort from India. *Ann Indian Acad Neurol* 2022; 25: 194-202.